NextCell Pharma Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
NXTCL
- Investments
-
1
- Share Price
-
$0.02
- (As of Thursday Closing)
NextCell Pharma General Information
Description
NextCell Pharma AB is a Swedish clinical-stage biotechnology company developing mesenchymal stromal cell (MSC)-based therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. Its key product candidate, ProTrans, is designed to preserve insulin-producing capacity in Type 1 Diabetes patients, while the company also operates Cellaviva, Scandinavia's private stem-cell bank, and QVance, which provides analytical and quality-control services for therapy medicinal products. It's operations are organized into three business areas: ProTrans (cell therapy development), Cellaviva (stem-cell banking), and QVance (ATMP analytical services). The company's activities are concentrated in Sweden and the Nordic region.
Contact Information
Website
www.nextcellpharma.comCorporate Office
- Karolinska Institutet Science Park
- Halsovagen 7
- 141 57 Huddinge
- Sweden
Corporate Office
- Karolinska Institutet Science Park
- Halsovagen 7
- 141 57 Huddinge
- Sweden
NextCell Pharma Stock Performance
As of 12-Nov-2026, NextCell Pharma’s stock price is $0.02. Its current market cap is $3.02M with 126M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.03 | $0.02 - $0.20 | $3.02M | 126M | 674K | -$0.04 |
NextCell Pharma Financials Summary
As of 31-Dec-2025, NextCell Pharma has a trailing 12-month revenue of $1.01M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Aug-2024 | FY 2023 31-Aug-2023 |
|---|---|---|---|---|
| EV | 4,649 | 4,649 | 7,042 | 5,585 |
| Revenue | 1,014 | 1,004 | 951 | |
| EBITDA | (3,811) | (3,974) | (3,813) | |
| Net Income | (4,005) | (3,952) | (3,743) | |
| Total Assets | 6,946 | 6,946 | 7,948 | 8,195 |
| Total Debt | 0 | 0 | 0 |
NextCell Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NextCell Pharma Patents
NextCell Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220323504-A1 | Allogeneic composition for the treatment of cns disorders | Pending | 15-Aug-2019 | ||
| US-20230302056-A1 | Allogeneic composition for the treatment of covid-19 | Pending | 15-Aug-2019 | ||
| AU-2020330745-A1 | Allogeneic composition for treatment of cns disorders | Active | 15-Aug-2019 | ||
| AU-2020330745-B2 | Allogeneic composition for treatment of cns disorders | Active | 15-Aug-2019 | ||
| CA-3148582-A1 | Allogeneic composition for treatment of cns disorders | Pending | 15-Aug-2019 | A61K35/28 |
NextCell Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NextCell Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NextCell Pharma Investments (1)
NextCell Pharma’s most recent deal was a Secondary Transaction - Private with FamiCordTx for . The deal was made on 22-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| FamiCordTx | 22-Jun-2021 | Secondary Transaction - Private | Drug Discovery |
NextCell Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
NextCell Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| QVance | Stockholm, Sweden | 2024 |
NextCell Pharma FAQs
-
When was NextCell Pharma founded?
NextCell Pharma was founded in 2014.
-
Where is NextCell Pharma headquartered?
NextCell Pharma is headquartered in Huddinge, Sweden.
-
What is the size of NextCell Pharma?
NextCell Pharma has 21 total employees.
-
What industry is NextCell Pharma in?
NextCell Pharma’s primary industry is Drug Discovery.
-
Is NextCell Pharma a private or public company?
NextCell Pharma is a Public company.
-
What is NextCell Pharma’s stock symbol?
The ticker symbol for NextCell Pharma is NXTCL.
-
What is the current stock price of NextCell Pharma?
As of 12-Nov-2026 the stock price of NextCell Pharma is $0.02.
-
What is the current market cap of NextCell Pharma?
The current market capitalization of NextCell Pharma is $3.02M.
-
What is NextCell Pharma’s current revenue?
The trailing twelve month revenue for NextCell Pharma is $1.01M.
-
What is NextCell Pharma’s annual earnings per share (EPS)?
NextCell Pharma’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
